Európska únia - nórčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostata neoplasmer - endokrin terapi - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Európska únia - nórčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatide - osteoporose - kalsiumhomeostase - sondelbay is indicated in adults. behandling av osteoporose hos postmenopausale kvinner og hos menn med økt risiko for brudd. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. behandling av osteoporose assosiert med vedvarende systemisk glukokortikoid terapi hos kvinner og menn med økt risiko for brudd.

Európska únia - nórčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triple kombinasjon terapi) som et tillegg til diett og trening hos pasienter ikke kontrollert på deres maksimal tolerert dose av metformin og en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.